Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
P/E ratio for Vera Therapeutics, Inc. (VERA)
P/E ratio as of 2023: -6.84
According to Vera Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -6.84. At the end of 2022 the company had a P/E ratio of -5.77.
P/E ratio history for Vera Therapeutics, Inc. from 2019 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -6.84 |
| 2022 | -5.77 |
| 2021 | -17.43 |
| 2020 | -0.80 |
| 2019 | -3.32 |